Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts

from BioCentury This Week · host BioCentury

Long-awaited proof of concept for AstraZeneca’s PARP-1-selective therapy opens the door to combination strategies previously limited by hematopoietic toxicity, Senior Editor Karen Tkach Tuzman says on the latest edition of BioCentury This Week. Tkach Tuzman surveys data from the growing DNA damage repair (DDR) field from this year’s American Association for Cancer Research meeting, and the team also discusses the legacy of outgoing NCI Director Ned Sharpless, concerns over McKinsey's work for FDA and life sciences clients and the latest crop of BioCentury Emerging Company Profiles. This week’s podcast is sponsored by Bio€quity Europe.Reach us by sending a text

Episode metadata supplied by the publisher feed · Published Apr 19, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts

0:00 20:23

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioCentury This Week?

This episode is 20 minutes long.

When was this BioCentury This Week episode published?

This episode was published on April 19, 2022.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!